Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial

NCT03773302 is registered in ClinicalTrials.gov with QED Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT03773302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03773302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial
Lead sponsor
QED Therapeutics, a BridgeBio company
Phase
Phase 3
Overall status
Terminated
Start date
December 27, 2019
Completion date
March 2, 2023
Enrollment
48 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cholangiocarcinoma, fgfr2 gene mutation